Immunotherapy of malignant melanoma


MUDr. Alexandr Poprach, Ph.D., MUDr. Radek Lakomý, Ph.D.

Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno



Metastatic and/or locally advanced inoperable melanoma is still an incurable disease. On the other hand the progress in the new treatment's options causes significant prolongation of time to progression and overall survival. Treatment of metastatic melanoma could be divided into three goups. Checkpoint inhibitors - anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1 (programmed death 1) or PD-L1 inhibitors - are in the first group, BRAF and MEK inhibitors belong to the second group. Cytostatics are in the last group. We will point out drugs from the first group in this review and the results of the actual studies will be mentioned.



immunotherapy, ipilimumab, nivolumab, pembrolizumab, survival



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...